Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Retatrutide (LY3437943 — GLP-1/GIP/Glucagon triple agonist)
Retatrutide (Eli Lilly code LY3437943) is an investigational triple-receptor agonist simultaneously targeting GLP-1, GIP, and glucagon receptors. It is research-only and NOT FDA-approved as of April 2026; the Phase 3 TRIUMPH program is ongoing with anticipated NDA filing in 2026. Published Phase 2 data showed roughly 24% mean body weight loss at 48 weeks on 12 mg weekly (Jastreboff, NEJM 2023).
Simultaneously activates three incretin and metabolic receptors: GLP-1R (glucose-dependent insulin secretion, appetite suppression, delayed gastric emptying), GIPR (insulin sensitization, adipose fat metabolism), and glucagon receptor (hepatic glucose output, thermogenesis, fatty acid oxidation). The glucagon-receptor component increases resting energy expenditure and hepatic fat mobilization — a mechanism absent in GLP-1 monotherapy and dual GLP-1/GIP agonists like tirzepatide. Half-life is approximately 6 days, enabling once-weekly subcutaneous dosing.
The Phase 2 trial demonstrated up to 24.2% body weight loss at 48 weeks at the highest dose (12 mg), exceeding results of both semaglutide and tirzepatide. Significant reductions in hepatic steatosis (fatty liver) were also observed. Phase 3 trials are ongoing with results expected in 2025–2026. Eli Lilly is the developer.
Typical Dose
2–12mg
Range
2–12mg (Phase 3 titration, weekly)
Frequency
1x/week (subcutaneous)
Route
SubQ
Duration
Phase 3 ongoing; titration typically 4-week steps from 2mg to 12mg
Reconstitution
Investigational — no approved formulation; bacteriostatic water volume varies by vial mg — see calculator
Notes
Phase 2 trial used escalating doses up to 12 mg once weekly. Titration schedule similar to other GLP-1 agonists, increasing dose every 4 weeks to minimize GI side effects. Not yet approved — all dosing is from clinical trial data.
Aggregated from 323 lab-verified Certificates of Analysis uploaded directly by 1 verified lab. Purity averages exclude values outside [50%, 100%] to filter unit-misreads.
COAs
323
Verified labs
1
Avg purity
99.75%
±0.24%
Endotoxin tested
43%
Tested by
These biomarkers are commonly tracked to assess response and safety. Run baseline labs before starting, mid-cycle labs halfway through, and post-cycle labs 1–2 weeks after the final dose.
This platform provides informational tools only, not medical advice. This information is for educational purposes only. Consult a licensed provider.
Disclosed Labs